Metastatic papillary thyroid carcinoma presenting with elevated serum levels of carbohydrate antigen 19-9 (CA19-9): a case report.

Anti-thyroglobulin antibody Carbohydrate antigen 19-9 (CA19-9) Liver metastasis Papillary thyroid carcinoma Thyroglobulin

Journal

Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125

Informations de publication

Date de publication:
16 Mar 2022
Historique:
received: 13 02 2022
accepted: 08 03 2022
entrez: 16 3 2022
pubmed: 17 3 2022
medline: 17 3 2022
Statut: epublish

Résumé

The major sites of distant metastases of papillary thyroid carcinoma (PTC) are the lung and bone; metastasis to the liver is rare. Although the postoperative serum thyroglobulin (Tg) level after total thyroidectomy is a good prognostic indicator for PTC when anti-thyroglobulin antibody (TgAb) is negative, the presence of TgAb interferes with the Tg assay, making serum Tg levels unreliable. Here we report a case of liver metastasis of PTC that presented with elevated serum levels of carbohydrate antigen 19-9 (CA19-9), which is usually a serum marker of pancreatic and gastrointestinal neoplasias. A 69-year-old man was diagnosed with PTC and underwent total thyroidectomy 16 years ago. The patient's serum Tg levels increased progressively during follow-up and his serum TgAb was negative. Positron emission tomography (PET) and computed tomography (CT) revealed metastases of the lung, cervical spine, mediastinum and liver. The liver lesion was a solitary tumor measuring 4.0 cm in the greatest dimension. His serum CA19-9 level was very high (326 U/mL), and intrahepatic cholangiocarcinoma was suspected from the results of various examinations including gastrointestinal endoscopic imaging and CT. Laparoscopic partial liver resection for segment 4 was performed. The histopathological diagnosis was a metastatic liver tumor from PTC. The immunohistological examination revealed that the liver tumor was positive for CA19-9 and Tg. The primary PTC, recovered from paraffin-embedded specimen, was also positive for CA19-9. After the surgery, his serum CA19-9 level as well as serum Tg level markedly decreased. We presented the first reported case of liver metastasis of a PTC presenting with elevated serum levels of CA19-9 after total thyroidectomy. This case suggests that the serum CA19-9 levels may serve as a surrogate marker for PTC in place of the serum Tg level in patients with positive serum TgAb if the PTC and/or the metastatic lesions are positive for CA19-9 staining.

Sections du résumé

BACKGROUND BACKGROUND
The major sites of distant metastases of papillary thyroid carcinoma (PTC) are the lung and bone; metastasis to the liver is rare. Although the postoperative serum thyroglobulin (Tg) level after total thyroidectomy is a good prognostic indicator for PTC when anti-thyroglobulin antibody (TgAb) is negative, the presence of TgAb interferes with the Tg assay, making serum Tg levels unreliable. Here we report a case of liver metastasis of PTC that presented with elevated serum levels of carbohydrate antigen 19-9 (CA19-9), which is usually a serum marker of pancreatic and gastrointestinal neoplasias.
CASE PRESENTATION METHODS
A 69-year-old man was diagnosed with PTC and underwent total thyroidectomy 16 years ago. The patient's serum Tg levels increased progressively during follow-up and his serum TgAb was negative. Positron emission tomography (PET) and computed tomography (CT) revealed metastases of the lung, cervical spine, mediastinum and liver. The liver lesion was a solitary tumor measuring 4.0 cm in the greatest dimension. His serum CA19-9 level was very high (326 U/mL), and intrahepatic cholangiocarcinoma was suspected from the results of various examinations including gastrointestinal endoscopic imaging and CT. Laparoscopic partial liver resection for segment 4 was performed. The histopathological diagnosis was a metastatic liver tumor from PTC. The immunohistological examination revealed that the liver tumor was positive for CA19-9 and Tg. The primary PTC, recovered from paraffin-embedded specimen, was also positive for CA19-9. After the surgery, his serum CA19-9 level as well as serum Tg level markedly decreased.
CONCLUSIONS CONCLUSIONS
We presented the first reported case of liver metastasis of a PTC presenting with elevated serum levels of CA19-9 after total thyroidectomy. This case suggests that the serum CA19-9 levels may serve as a surrogate marker for PTC in place of the serum Tg level in patients with positive serum TgAb if the PTC and/or the metastatic lesions are positive for CA19-9 staining.

Identifiants

pubmed: 35292876
doi: 10.1186/s40792-022-01397-7
pii: 10.1186/s40792-022-01397-7
pmc: PMC8924338
doi:

Types de publication

Journal Article

Langues

eng

Pagination

45

Informations de copyright

© 2022. The Author(s).

Références

Lab Invest. 1989 May;60(5):726-32
pubmed: 2716285
Surg Today. 2014 Nov;44(11):2157-61
pubmed: 24407283
J Clin Endocrinol Metab. 2015 Aug;100(8):E1074-83
pubmed: 26079778
Thyroid. 2021 Jul;31(7):1050-1055
pubmed: 33234054
Nihon Gan Chiryo Gakkai Shi. 1984 Jul 20;19(6):1289-95
pubmed: 6595323
Endocr Pract. 2017 Oct;23(10):1193-1200
pubmed: 28704099
Endocrinol Jpn. 1991 Oct;38(5):565-71
pubmed: 1843277
Surg Case Rep. 2020 Jun 18;6(1):142
pubmed: 32556940
Ochsner J. 2021 Summer;21(2):224-229
pubmed: 34239388
World J Surg. 2018 Mar;42(3):615-622
pubmed: 29349484
J Clin Endocrinol Metab. 2014 Dec;99(12):4589-99
pubmed: 25226290
Int J Surg Case Rep. 2015;6C:146-9
pubmed: 25536153
Endocrinol Diabetes Metab Case Rep. 2020 Aug 20;2020:
pubmed: 32820131
Eur Thyroid J. 2019 Jul;8(4):186-191
pubmed: 31602360
Ann Surg Oncol. 2015 Feb;22(2):460-6
pubmed: 25192681
Langenbecks Arch Chir. 1995;380(5):269-72
pubmed: 7500798
Pediatr Blood Cancer. 2005 Jul;45(1):64-7
pubmed: 15770642
Eur J Endocrinol. 2015 Sep;173(3):297-304
pubmed: 26034076
Endocrinol Jpn. 1990 Apr;37(2):247-54
pubmed: 1699752

Auteurs

Minoru Kihara (M)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan. kihara@kuma-h.or.jp.

Akira Miyauchi (A)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Mitsuyoshi Hirokawa (M)

Department of Diagnostic Pathology, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Makoto Fujishima (M)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Hiroo Masuoka (H)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Takuya Higashiyama (T)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Naoyoshi Onoda (N)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Yasuhiro Ito (Y)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Akihiro Miya (A)

Departments of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.

Classifications MeSH